Finally, delivery of SBRT for patients with oligometastatic NSCLC could significantly prolong PFS compared with historical controls, whether prior systemic treatment was chemotherapy or EGFR‐TKI therapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.